文献速递心境障碍精神分裂症与精神病性障碍会诊联络精神医学

妊娠早期继续使用非典型抗精神病药与妊娠期糖尿病风险

Continuation of Atypical Antipsychotic Medication During Early Pregnancy and the Risk of Gestational Diabetes.
PubMed 文献 · Am J Psychiatry · 2018-05-07

该研究基于2000-2010年Medicaid数据,纳入孕前3个月曾配药的非糖尿病孕妇,比较妊娠前半期继续使用或停用五种非典型抗精神病药者的妊娠期糖尿病风险。调整混杂后,继续使用奥氮平或喹硫平者风险升高,阿立哌唑、齐拉西酮和利培酮未见显著升高。

要点

  • 继续使用奥氮平者妊娠期糖尿病调整相对风险为1.61(95%CI=1.13-2.29)。
  • 继续使用喹硫平者调整相对风险为1.28(95%CI=1.01-1.62)。
  • 阿立哌唑、齐拉西酮和利培酮未显示显著风险升高。

核心结论

  • 与孕前停用非典型抗精神病药者相比,妊娠前半期继续使用奥氮平或喹硫平者妊娠期糖尿病风险升高,可能与该两药代谢效应有关。

研究设计与样本

  • 基于2000-2010年Medicaid数据库的回顾性队列研究,纳入孕前3个月至少一次配药且活产的非糖尿病孕妇。
  • 在1,543,334次妊娠中,基线使用阿立哌唑(N=1,924)、齐拉西酮(N=673)、喹硫平(N=4,533)、利培酮(N=1,824)或奥氮平(N=1,425)者纳入分析。
  • 妊娠前半期配药≥2次者为继续组,无配药者为停用组;采用广义线性模型和倾向评分分层调整混杂,估计妊娠期糖尿病绝对风险和相对风险。

主要发现

  • 继续用药者总体合并症更多、基线抗精神病药使用时间更长。
  • 妊娠期糖尿病粗风险(继续组 vs 停用组):阿立哌唑4.8% vs 4.5%,齐拉西酮4.2% vs 3.8%,喹硫平7.1% vs 4.1%,利培酮6.4% vs 4.1%,奥氮平12.0% vs 4.7%。
  • 调整后相对风险:阿立哌唑0.82(95%CI=0.50-1.33),齐拉西酮0.76(95%CI=0.29-2.00),喹硫平1.28(95%CI=1.01-1.62),利培酮1.09(95%CI=0.70-1.70),奥氮平1.61(95%CI=1.13-2.29)。

关键数值与推荐

  • 继续使用奥氮平者妊娠期糖尿病调整相对风险为1.61(95%CI=1.13-2.29)。
  • 继续使用喹硫平者调整相对风险为1.28(95%CI=1.01-1.62)。
  • 阿立哌唑、齐拉西酮和利培酮调整相对风险置信区间均包含1,未达统计学显著。

临床怎么用

  • 对妊娠前半期继续使用奥氮平或喹硫平者,应加强妊娠期糖尿病筛查与代谢监测。
  • 对阿立哌唑、齐拉西酮或利培酮继续使用者,仍需个体化评估代谢风险。
  • 临床决策需权衡继续用药的精神科获益与妊娠期糖尿病风险。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Some atypical antipsychotics are associated with metabolic side effects, which are risk factors for gestational diabetes. The authors examined the risk of developing gestational diabetes associated with the continuation of treatment with aripiprazole, ziprasidone, quetiapine, risperidone, and olanzapine during pregnancy compared with discontinuation of these antipsychotic drugs. METHOD: Nondiabetic pregnant women who were linked to a live-born infant and enrolled in Medicaid (2000-2010) and who received one or more prescriptions dispensed for an antipsychotic drug during the 3 months before pregnancy were included in the analyses. Among 1,543,334 pregnancies, some expectant mothers at baseline were receiving treatment with aripiprazole (N=1,924), ziprasidone (N=673), quetiapine (N=4,533), risperidone (N=1,824), or olanzapine (N=1,425). For each antipsychotic drug, women with two or more dispensings ("continuers") were compared with women with no dispensings ("discontinuers") during the first half of pregnancy. A generalized linear model and propensity-score stratification were used to obtain absolute and relative risks of developing gestational diabetes, with adjustment for confounders. RESULTS: Women who continued antipsychotic treatment during pregnancy generally had higher comorbidity and longer baseline antipsychotic use. The crude risk of developing gestational diabetes among continuers compared with discontinuers, respectively, was 4.8% and 4.5% for aripiprazole, 4.2% and 3.8% for ziprasidone, 7.1% and 4.1% for quetiapine, 6.4% and 4.1% for risperidone, and 12.0% and 4.7% for olanzapine. The adjusted relative risks were 0.82 (95% CI=0.50-1.33) for aripiprazole, 0.76 (95% CI=0.29-2.00) for ziprasidone, 1.28 (95% CI=1.01-1.62) for quetiapine, 1.09 (95% CI=0.70-1.70) for risperidone, and 1.61 (95% CI=1.13-2.29) for olanzapine. CONCLUSIONS: Compared with women who discontinued use of an atypical antipsychotic medication before the start of pregnancy, women who continued treatment with olanzapine or quetiapine had an increased risk of gestational diabetes that may be explained by the metabolic effects associated with these two drugs.

来源:Am J Psychiatry,查看原文。版权归原作者所有。

引用

  1. Park Y, Hernandez-Diaz S, Bateman BT, et al. Continuation of Atypical Antipsychotic Medication During Early Pregnancy and the Risk of Gestational Diabetes. Am J Psychiatry. 2018. PMID: 29730938. doi:10.1176/appi.ajp.2018.17040393

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。